Myofilament dysfunction significantly contributes to impaired ventricular relaxation in diastolic heart failure, highlighting sarcomeric proteins as potential targets for novel therapeutic interventions.
Diastolic heart failure (DHF), in which impaired ventricular filling leads to typical heart failure symptoms, represents over 50% of all heart failure cases and is linked with risk factors, including metabolic syndrome, hypertension, diabetes, and aging. A substantial proportion of patients with this disorder maintain normal left ventricular systolic function, as assessed by ejection fraction. Despite the high prevalence of DHF, no effective therapeutic agents are available to treat this condition, partially because the molecular mechanisms of diastolic dysfunction remain poorly understood. As such, by focusing on the underlying molecular and cellular processes contributing to DHF can yield new insights that can represent an exciting new avenue and propose a novel therapeutic approach for DHF treatment. This review discusses new developments from basic and clinical/translational research to highlight current knowledge gaps, help define molecular determinants of diastolic dysfunction, and clarify new targets for treatment.
Aboonabi et al. (Sat,) conducted a review in Diastolic heart failure. Myofilament dysfunction significantly contributes to impaired ventricular relaxation in diastolic heart failure, highlighting sarcomeric proteins as potential targets for novel therapeutic interventions.